Selling and marketing expenses for the quarter ended June 30, 2012 were $0.6 million, compared to $0.2 million for the quarter ended June 30, 2011. The increase was primarily due to increases in consulting fees and personnel costs as we prepare for the potential commercialization of Ravicti in UCD.
About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy.
Forward-Looking Statements:To the extent that statements contained in this press release are not descriptions of historical facts regarding Hyperion, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our expectations regarding the timing of any commercial launch of Ravicti as well as the use of the initial public offering proceeds. Forward-looking statements in this release involve substantial risks and uncertainties that could cause future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks related to: the uncertain clinical development process; that the U.S. Food and Drug Administration may not be satisfied with preclinical data, including carcinogenicity data; the ability to obtain, and timing of, regulatory approval of Ravicti for the treatment of UCD or the success and timing of commercialization efforts; the fact that the patient population suffering from UCD is small and has not been established with precision; the ability to obtain adequate clinical supplies of Ravicti; and the ability to raise sufficient capital to complete the development and commercialize Ravicti in UCD. Hyperion undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see the company's prospectus dated July 25, 2012, filed with the Securities and Exchange Commission.
|Hyperion Therapeutics, Inc.|
|Condensed Consolidated Statements of Operations|
|(In thousands, except share and per share amounts)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Research and development||$ 2,732||$ 4,632||$ 11,640||$ 8,932|
|General and administrative||1,469||2,488||3,540||3,849|
|Selling and marketing||554||217||800||467|
|Total operating expenses||4,755||7,337||15,980||13,248|
|Loss from operations||(4,755)||(7,337)||(15,980)||(13,248)|
|Other income (expense), net||(1,128)||52||(753)||52|
|Net loss attributable to common stockholders||$ (7,162)||$ (8,124)||$ (19,048)||$ (14,031)|
|Net loss per share attributable to common stockholders:|
|Basic and diluted||$ (15.26)||$ (17.31)||$ (40.59)||$ (29.90)|
|Weighted average number of shares used to compute net loss per share of common stock:|
|Basic and diluted||469,319||469,319||469,319||469,319|
|Hyperion Therapeutics, Inc.|
|Condensed Consolidated Balance Sheets|
|June 30,||December 31,|
|Cash and cash equivalents||$ 7,299||$ 7,018|
|Prepaid expenses and other current assets||436||741|
|Total current assets||7,735||8,064|
|Deferred offering costs||1,375||—|
|Property and equipment, net||25||19|
|Other non-current assets||447||34|
|Total assets||$ 9,582||$ 8,142|
|Liabilities, Convertible Preferred Stock and Stockholders' Deficit|
|Accounts payable||$ 1,955||$ 1,887|
|Call option liability||—||737|
|Convertible notes payable||31,153||23,412|
|Notes payable, current portion||1,705||—|
|Total current liabilities||39,142||29,346|
|Notes payable, net of current portion||7,651||—|
|Convertible preferred stock||58,326||58,326|
|Additional paid-in capital||25,679||24,630|
|Deficit accumulated during the development stage||(125,782)||(106,734)|
|Total stockholders' deficit||(100,103)||(82,104)|
|Total liabilities, convertible preferred stock and stockholders' deficit||$ 9,582||$ 8,142|
CONTACT: Shari Annes, Investor Relations Cell: 650 888 0902 email@example.com
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV